The Use of the 5-HT₃ Receptor Antagonist Tropisetron in Trigger Point Therapy: A Pilot Study

REFERENCES

• Mense S, Simons D G, Russell I J. Muscle pain. Understanding its nature, diagnosis and treatment. Lippincott Williams & Wilkins, BaltimoreUSA 2001
   Google Scholar
• Simons D G. Diagnostic criteria of myofascial pain caused by trigger points. J. Musculoskeletal Pain 1999; 7(1/2)111–120
   Google Scholar
• Simons D G. Clinical and etiological update of myofascial pain from trigger points. J. Musculoskeletal Pain 1996; 4(1/2)93–121
   Google Scholar
• Brückle W, Suckfüll M, Fleckenstein W, Weiss C, Gewebe Müller W. Po2-Messung in der verspannten Rückenmuskulatur (merector spinae). Zschr. Rheumatol. 1990; 49: 208–216
   PubMed Web of Science ®Google Scholar
• Shah J P, Phillips T, Danoff J V, Gerber L H. A novel microanalytical technique for assaying soft tissue demonstrates significant quantitative biochemical differences in 3 clinically distinct groups: Normal, latent, and active. Arch. Phys. Med. and Rehab. 2003; 84, Nr. 9, Abstr. 17
   Google Scholar
• Janovic J, Schwarz K. Therapeutic uses of botulinum toxin. N. Engl. J. Med. 1991; 342: 1186–1194
   Google Scholar
• Wheeler A H. The therapeutic uses of botulinum toxin. Amer. Fam. Physician 1997; 55: 541–545
   PubMed Web of Science ®Google Scholar
• Stratz T, Stauber A, Müller W. Tropisetron in the treatment of myofascial pain. Caused by trigger points. Ann. Rheum. Dis. 61;Suppl. 2002; 1, 170
   Google Scholar
• Rachlin E S. Trigger points. Trigger points. Management, E S Rachling. Mosby, St. Louis 1994; 145–147, Myofascial pain and Fibromyalgia
   Google Scholar
• Travell J G, Simons D G, Fricton J, Bennett R M, Goldenberg D L, Gerwin R, Hathaway D, et al. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J. Rheum. 1992; 19: 944–951
   PubMedGoogle Scholar
• Simons D G. Referred phenomena of myofascial trigger points. New trends in referred pain ald hyperalgesia, L D Vecchiet, D Albe-fessard, U Lindblom, M A Gimaberardino. Elsevier Science Publishers, 341–357, 1003
   Google Scholar
• Aun N C. Treating subjective shortness of breath by inactivating trigger points of levator scapular muscles with acupuncture needles. J. Musculoskelet. Pain 1996; 4(3)81–85
   Google Scholar
• Gundersen C B. The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog. Neurobiol. 1980; 14, 99
   PubMedGoogle Scholar
• Wheeler A H, Goolkasian P, Gretz StS. Botulinum toxin A for the treatment of chronic neck pain. Pain 2001; 94: 255–260
   PubMed Web of Science ®Google Scholar
• Stratz T, Färber L, Müller W. Local treatment of tendinopathies: A comparison between tropisetron and depot corticosteroids combined with local anesthetics. Scand. J. Rheumatol. 2002; 31: 366–370
   PubMed Web of Science ®Google Scholar
• Samborski W, Atarowska M, Stratz T, Zaba R, Mackiewicz S, Müller W, Lacki J. Intra-articular tropisetron compared with methylprednisolone acetate in knee involvement in osteoarthritis and rheumatoid arthritis. Preliminary report. Ann. Rheum. Dis. 2003; 62, Suppl. 1:405
   Google Scholar
• Stratz T, Müller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases-a clue to the mechanism of action of these agents in fibromyalgia? Scand. J. Rheumatol. 29;Suppl. 2000; 113: 66–71
   PubMedGoogle Scholar
• Richardson B P, Engel G, Donatsch P, Stadler P A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 126–131
   PubMed Web of Science ®Google Scholar
• Glaum S R, Proudfit H K, Andersen E G. 5-HT3-receptors modulate spinal nociceptive reflexes. Brain Res. 1990; 510: 12–16
   PubMed Web of Science ®Google Scholar
• Giordano J, Daleo C, Sacks S M. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur. J. Pharmacol. 1998; 354: 13–14
   PubMed Web of Science ®Google Scholar
• Zeitz K P, Guy N, Malmberg A B, Dirajlal S, Martin W S, Sun L, Bonhaus D W, Stucky C L, Julius D. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J. Neurosci. 2002; 22: 1010–1019
   PubMed Web of Science ®Google Scholar
• Greenshaw A J, Silverstone P H. The non-anti-emetic uses of serotonin 5-HT3-receptor antagonists. Drug 1997; 55: 20–39
   Google Scholar
• Ambesh S P, Dubey P K, Sinha P K. Ondansetron pretreatment to alleviate pain on propofol injection: A randomized, controlled, double-blind study. Anesth. Analg. 1999; 89: 197–199
   PubMed Web of Science ®Google Scholar
• Ali Z, Wu G, Kozlov A, Barasi S. The role of 5-HT3 in nociceptive processing in the rat spinal cord: Results from behavioural and electrophysiological studies. Neuroscience Letters 1996; 208: 203–207
   PubMed Web of Science ®Google Scholar
• Saria A, Javorsky F, Humpel C, Gamse R. 5-HT3- receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990; 1: 104–106
   PubMedGoogle Scholar
• Inoue A, Hashimoto T, Hide I, Nishio H, Nkata Y. 5Hydroxytrytamine-facilitates release of substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP. J. Neurochem. 1997; 68: 128–133
   PubMed Web of Science ®Google Scholar
• Levine J D, Clark R, Devor M, Helms C, Moskowitz M A, Basbaum A I. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984; 226: 547–549
   PubMed Web of Science ®Google Scholar
• Lotz M, Carson D A, Vaughan J H. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987; 235: 893–895
   PubMed Web of Science ®Google Scholar
• Menkes C J, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F. Substance P levels in the synovium fluid from patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 1993; 20: 714–717
   PubMed Web of Science ®Google Scholar
• Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vasquez J J, Gijon-Banos J, Hernanz A. Neuro-peptides and interleukin-6 in human joint inflammation; relationship between intraarticular substance P and interleukin-6 concentration. Neurosci. Lett. 1994; 170: 251–254
   PubMed Web of Science ®Google Scholar
• Fiebich B L, Akundi R S, Lieb K, Candelario-Jalil E, Gmeiner D, Haus U, Müller W, Stratz T, Munoz E. Anti-inflammatory effects of the 5-HT3-receptor antagonists tropisetron in lipopolysaccharide-stimulated primary human monocytes. Scand. J. Rheumatol. 2004; 33, Suppl. 119: 28–332
   Google Scholar
• Khan N A, Poisson J P. 5-HT3-receptor-channels coupled with NA+ influx in human T cells: role in T cell activation. J. Neuroimmunol. 1999; 99: 53–60
   PubMed Web of Science ®Google Scholar